DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Papaverine is an investigational drug.
There have been 16 clinical trials for Papaverine. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2019.
The most common disease conditions in clinical trials are Erectile Dysfunction, Enuresis, and Cognition Disorders. The leading clinical trial sponsors are Cairo University, National Cancer Institute (NCI), and Ohio State University Comprehensive Cancer Center.
There are two US patents protecting this investigational drug and twenty-one international patents.
Recent Clinical Trials for Papaverine
|Effect of Papaverine on Renal Artery Blood Flow Volume||Asan Medical Center||Phase 4|
|Papaverine vs Heparin for Peripheral Arterial Catheter Patency in Pediatric Patients||The University of Texas Health Science Center, Houston||Phase 4|
|Intracavernous Injection of Botox 100 U for Treatment of PDE5Is Inconvenient Patients With ED||Benha University||Phase 2/Phase 3|
Top disease conditions for Papaverine
Top clinical trial sponsors for Papaverine
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Papaverine||Start Trial||Methods and compositions for treating infection||UNIVERSITY OF ROCHESTER (Rochester, NY) UNIVERSITY OF KANSAS (Lawrence, KS)||Start Trial|
|Papaverine||Start Trial||Implantable human liver tissue constructs and uses thereof||Massachusetts Institute of Technology (Cambridge, MA)||Start Trial|
|Papaverine||Start Trial||Cytochrome P450 fusion protein||The University of York (York, GB) Sun Pharmaceutical Industries (Australia) Pty Ltd (Notting Hill, Victoria, AU)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Papaverine||World Intellectual Property Organization (WIPO)||2014052836||2032-09-27||Start Trial|
|Papaverine||World Intellectual Property Organization (WIPO)||2012048170||2030-10-06||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|